After describing BRCA1/2 alterations and reversion mutations that impact PARPi sensitivity and efficiency, we will further analyze the role of circulating tumor DNA (ctDNA) sequencing to detect them and improve therapeutic strategy. This evidence concerns the gene BRCA1 and neoplasm.